Skip to Content

'
Jorge E. Cortes, M.D.

Present Title & Affiliation

Primary Appointment

Internist and Professor, Deputy Chair, Department of Leukemia, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX
Chair, CML Section, Department of Leukemia, Division of Cancer Medicine, UT M.D. Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Member, Graduate Faculty, The University of Texas Graduate School of Biomedical Sciences, Houston, TX

Education & Training

Degree-Granting Education

1986 Facultad de Medicina, Universidad Nacional Autónoma de Mexico, Mexico City, Mexico, MD, Medicine
1979 Centro Universitario Mexico, Mexico City, Mexico, BS, Biological Sciences

Postgraduate Training

1/2004 The Essential Training Program for All Medical Staff Leaders, Medical Executive Committee Institute, Rancho Mirage, CA
2003-2004 Faculty Leadership Academy Executive Class, University of Texas MD Anderson Cancer Center, Houston, TX
1993-1995 Hematology/Oncology Fellowship, Hematology/Oncology, University of Texas MD Anderson Cancer Center, Houston, TX
1991-1992 Hematology Fellowship, University of Texas Health Science Center at Houston, Houston, TX
1990-1992 Hematology Fellowship, Instituto Nacional de la Nutricion Salvador Zubiran, Mexico City, Mexico
1989-1990 Medical Chief Resident, Instituto Nacional de la Nutricion Salvador Zubiran, Mexico City, Mexico
1986-1989 Residency in Internal Medicine, Instituto Nacional de la Nutricion Salvador Zubiran, Mexico City, Mexico
1985 Mini Residency Course in Internal Medicine, Mount Sinai Medical Center, Miami Beach, FL
1984 Pregraduate Internship, Hospital General de Mexico, SSA, Mexico City, Mexico

Board Certifications

1992 Hematology Board Certification, Mexican Board of Hematology
1989 Internal Medicine Board Certification, Mexican Board of Internal Medicine

Experience/Service

Academic Appointments

Associate Professor, Department of Leukemia, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX, 2008-2009
Associate Internist and Associate Professor, Deputy Chair, Department of Leukemia, Division of Cancer Medicine, UT M.D. Anderson Cancer Center, Houston, TX, 2002-2004
Associate Internist and Associate Professor, Department of Bioimmunotherapy, Division of Cancer Medicine, UT M.D. Anderson Cancer Center, Houston, TX, 1999-2002
Associate Internist and Associate Professor, Department of Leukemia, Division of Cancer Medicine, UT M.D. Anderson Cancer Center, Houston, TX, 1999-2002
Assistant Internist and Assistant Professor, Department of Bioimmunotherapy, Division of Cancer Medicine, UT M.D. Anderson Cancer Center, Houston, TX, 1996-1999
Assistant Internist and Assistant Professor, Department of Leukemia, Division of Cancer Medicine, UT M.D. Anderson Cancer Center, Houston, TX, 1996-1999
Associate Professor, Postgraduate Course of Hematology, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico, 1995-1996
Chairman, Department of Hematology and Oncology, Instituto Nacional de la Nutricion, Salvador Zubiran, Mexico, 1995-1996
Assistant Professor, Department of Histology, Medical School, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico, 1981

Administrative Appointments/Responsibilities

Deputy Chair, Department of Leukemia, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 2002-present
Chairman, Department of Hematology and Oncology, Instituto Nacional de la Nutricion Salvador Zubiran, Mexico City, Mexico, 1995-1996

Other Appointments/Responsibilities

Member, ASH Journal Committee, American Society of Hematology, Washington, DC, 1/2009-present
Co-Chair, Center for International Blood & Marrow Transplant Research - Chronic Leukemia Working Committee, Milwaukee, WI, 3/2008-3/2013
Member, Board of Directors, Leukemia & Lymphoma Society, White Plains, NY, 2007-present
Member, Scientific Advisory Board, The Max Foundation, Buenos Aires, Argentina, 2006-present
Abstract Selection Committee, American Society of Hematology, Washington, DC, 2006
Member, Patient Services Committee, Leukemia & Lymphoma Society, White Plains, NY, 2005-present
Member, Advisory Board, TX Gulf Coast Chapter, Leukemia & Lymphoma Society, Houston, TX, 2005-present
Abstract Selection Committee, American Society of Hematology, Washington, DC, 2003

Consultantships

Astra Zeneca, Washington, DC, 2003
Schering Plough, Kenilworth, NJ, 2002-present
Jensen, Dallas, TX, 2001-present
Glaxo Smith-Kline, Geneva, Switzerland, 1998-2001
Rhone-Poulenc Rorer, Los Angeles, CA, 1998

Institutional Committee Activities

Member, Clinician Educator Task Force, 2007-present
ID Chair, Search Committee, 2003-present
Vice Chair, IRB5, 2003-present
Vice Chair, Clinical Research Committee, 2003-2005
Member, Executive Committee of the Faculty Senate, 2003
Member, Clinical Research Committee, 2002-2003
Member, IRB Subcommittee (to develop policies and procedures for interactions with outside physicians), 2002
Member, Blue Ribbon Committee - Review of Clinical Trials Research, 2002
Chair, Department of Leukemia Protocol Compliance Monitoring Committee, 2001-present
Member, Infection Control Subcommittee, 2001-present
Chair, ICU Committee, 2001-present
Member, CTRC Committee, 2001-2002
Member, Clinical Council Sub-Committee for Clinical Research, 2001-2002
Chair, Search Committee, Pulmonary Medicine, 2001
Chair, Search Committee, Critical Care, 2001
Member, Search Committee, ID Faculty (Virologist), 2001
Representative for Leukemia Department, Faculty Senate, 2000-2003
Vice Chair, Transfusion Committee, 1999-present
Vice Chair, ICU Committee, 1999-2000
Member, ATC Task Force, 1999-2000
Chair, Transfusion Guidelines Sub-Committee, 1999
Member, Latin American Task Force, 1998-present
Member, Fellowship Committee, 1998-present

Honors and Awards

2008 Establishment of the Jorge Cortes Lecture, Agrupacion Mexicana Para el Estudio de la Hematologia
2007 Service to Mankind Award, The Leukemia & Lymphoma Society
2007 The Otis W. and Pearl L. Walters Faculty Achievement Award in Clinical Research, UT MD Anderson Cancer Center
2006 The Dr. John J. Kenny Award, The Leukemia & Lymphoma Society
2005 Annual Celgene Young Investigator Achievement Award for Clinical Research in Hematology, Celgene
2003 Faculty Scholar Award, UT MD Anderson Cancer Center
2002 Who's Who, Kingston's National Registry
2000 Faculty Excellence Award, UT MD Anderson Cancer Center
2000 Scholar in Clinical Research, The Leukemia & Lymphoma Society (formerly Leukemia Society of America)
1998-1999 Teacher of the Year, Medical Oncology, UT MD Anderson Cancer Center
1995 Aida Weiss Award, 1st Place Scientific Research Protocols Aida Weiss Foundation, and Programa Universitario de Investigacion en Salud, UNAM
1995 Merit Award, American Society of Clinical Oncology
1995 UPJohn "Outstanding Research Award", UT MD Anderson Cancer Center
1994 Clinical Fellows Research Award, UT MD Anderson Cancer Center
1994 Travel Award, American Society of Hematology
1986 First Place Award and Gabino Barreda Medal (for the highest school average during medical school), Universidad Nacional Autonoma de Mexico

Professional Memberships

Agrupacion Mexicana para el Estudio de la Hematologia, Mexico
Member, 1995-present
American Association for Cancer Research
Member, 1997-present
American Society of Clinical Oncology (ASCO)
Member, 1995-present
American Society of Hematology (ASH)
Member, 1994-present
Ecuatorian Oncology Research Group (GOIE)
Honorary Member, 1996-present
Harris County Medical Society, Houston, TX
Member, 1997-present
Medica Sur Medical Society, Mexico
Member, 1993-present
Medical Society of the Instituto Nacional de la Nutricion Salvador Zubiran, Mexico
Member, 1987-present
Mexican Association of Internal Medicine, Mexico
Member, 1989-present
NCI-ASH Hematology Clinical Trials Workshop Steering Committee, Washington, DC
Member, 2009-present
Texas Medical Association, TX
Member, 1997-present

Selected Publications

Peer-Reviewed Original Research Articles
1. Quintas-Cardama A, Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Rios MB, Hayes K, Glassman A, Bekele BN, Zhou X, Cortes J. Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood 105(6):2281-6, 2005. PMID: 15572595.
2. Cortes J, Faderl S, Estey E, Kurzrock R, Thomas D, Beran M, Garcia-Manero G, Ferrajoli A, Giles F, Koller C, O'Brien S, Wright J, Bai SA, Kantarjian H. Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes. J Clin Oncol 23(12):2805-12, 2005. PMID: 15728224.
3. Cortes J, Talpaz M, O'Brien S, Jones D, Luthra R, Shan J, Giles F, Faderl S, Verstovsek S, Garcia-Manero G, Rios MB, Kantarjian H. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 11(9):3425-32, 2005. PMID: 15867244.
4. Kantarjian H, Talpaz M, O'Brien S, Giles F, Faderl S, Verstovsek S, Garcia-Manero G, Shan J, Rios MB, Champlin R, de Lima M, Cortes J. Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience. Cancer 103(10):2099-108, 2005. PMID: 15830345.
5. Kantarjian HM, Bueso-Ramos CE, Talpaz M, O'Brien S, Giles F, Rios MB, Shan J, Cortes J. The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy. Leuk Lymphoma 46(7):993-7, 2005. PMID: 16019549.
6. Kantarjian HM, Bueso-Ramos CE, Talpaz M, O'Brien S, Giles F, Faderl S, Wierda W, Rios MB, Shan J, Cortes J. Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy. Cancer 104(4):777-80, 2005. PMID: 15971197.
7. Cortes J, Kantarjian H. New targeted approaches in chronic myeloid leukemia. J Clin Oncol 23(26):6316-24, 2005. PMID: 16155014.
8. Borthakur G, Kantarjian H, Daley G, Talpaz M, O'Brien S, Garcia-Manero G, Giles F, Faderl S, Sugrue M, Cortes J. Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy. Cancer 106(2):346-52, 2006. PMID: 16342165.
9. Ault P, Kantarjian H, O'Brien S, Faderl S, Beran M, Rios MB, Koller C, Giles F, Keating M, Talpaz M, Cortes J. Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol 24(7):1204-8, 2006. PMID: 16446320.
10. Cortes JE, Talpaz M, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Verstovsek S, Rios MB, Shan J, Kantarjian HM. Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal. Cancer 106(6):1306-15, 2006. PMID: 16463391.
11. Kantarjian HM, Cortes J. New strategies in chronic myeloid leukemia. Int J Hematol 83(4):289-93, 2006. PMID: 16757426.
12. Kantarjian HM, Talpaz M, O'Brien S, Jones D, Giles F, Garcia-Manero G, Faderl S, Ravandi F, Rios MB, Shan J, Cortes J. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood 108(6):1835-40, 2006. PMID: 16709931.
13. Quintas-Cardama A, Cortes JE. Chronic myeloid leukemia: diagnosis and treatment. Mayo Clin Proc 81(7):973-88, 2006. PMID: 16835977.
14. Alvarez RH, Kantarjian HM, Cortes J. The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors. Cancer 107(8):1918-29, 2006.
15. Kovitz C, Kantarjian H, Garcia-Manero G, Abruzzo LV, Cortes J. Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. Blood 108(8):2811-3, 2006. PMID: 16809614.
16. Quintas-Cardama A, Kantarjian H, O'Brien S, Jabbour E, Giles F, Ravandi F, Faderl S, Pierce S, Shan J, Verstovsek S, Cortes J. Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia. Cancer 107(7):1525-9, 2006. PMID: 16955510.
17. Jabbour E, Kantarjian H, Jones D, Talpaz M, Bekele N, O'Brien S, Zhou X, Luthra R, Garcia-Manero G, Giles F, Rios MB, Verstovsek S, Cortes J. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 20(10):1767-73, 2006. PMID: 16855631.
18. Quintas-Cardama A, Kantarjian H, Cortes J. Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib. Future Oncol 2(6):655-65, 12/2006. PMID: 17155893.
19. Jabbour E, Kantarjian H, O'Brien S, Rios MB, Abruzzo L, Verstovsek S, Garcia-Manero G, Cortes J. Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate. Blood 107:480-2, 2006. PMID: 16195326.
20. Cortes J. Overcoming drug resistance in chronic myeloid leukemia. Curr Opin Hematol 13(2):79-86, 2006. PMID: 16456373.
21. Quintas-Cardama A, Cortes J. Kinase inhibitors in chronic myelogenous leukemia. Clin Adv Hematol Oncol 4(5):365-74, 2006. PMID: 16728945.
22. Kantarjian HM, Talpaz M, Giles F, O'Brien S, Cortes J. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med 145(12):913-23, 12/2006. PMID: 17179059.
23. Quintas-Cardama A, Kantarjian H, Jones D, Nicaise C, O'Brien S, Giles F, Talpaz M, Cortes J. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood 109(2):497-9, 2007. PMID: 16990591.
24. Quintas-Cardama A, Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Estrov Z, Giles F, Murgo A, Ladie N, Verstovsek S, Cortes J. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer 109(2):248-55, 2007. PMID: 17154172.
25. Atallah E, Cortes J. Optimal initial therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phase. Curr Opin Hematol 14(2):138-44, 2007. PMID: 17255791.
26. Quintas-Cardama A, Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Ravandi F, Giles F, Thomas D, Wierda W, Cortes J. A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase. Leuk Lymphoma 48(2):283-9, 2007. PMID: 17325887.
27. Kantarjian HM, Giles F, Quintas-Cardama A, Cortes J. Important therapeutic targets in chronic myelogenous leukemia. Clin Cancer Res 13(4):1089-97, 2007. PMID: 17317816.
28. Jabbour E, Kantarjian H, Cortes J. Clinical activity of tipifarnib in hematologic malignancies. Expert Opin Investig Drugs 16(3):381-92, 2007. PMID: 17302532.
29. Kantarjian H, Schiffer C, Jones D, Cortes J. Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. Blood 111(4):1774-80, 2008. PMID: 18055868.
30. Cortes JE. Imatinib therapy for chronic myeloid leukemia: where do we go now? J Clin Oncol 26(20):3308-9, 2008. PMID: 18519950.
31. Jabbour E, Kantarjian HM, Jones D, Reddy N, O'Brien S, Garcia-Manero G, Burger J, Cortes J. Characteristics and outcome of patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood, 9/2008. PMID: 18818391.
32. Quintas-Cardama A, Cortes J. Molecular biology of BCR-ABL1-positive chronic myeloid leukemia. Blood 113(8):1619-30, 9/2008. PMID: 18827185.
33. Aribi A, Kantarjian H, Koller C, Thomas D, Faderl S, Garcia-Manero G, Cortes J. The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer 113(6):1338-43, 9/2008. PMID: 18629842.
34. Fava C, Cortes J. Philadelphia-negative acute myeloid leukemia with new chromosomal abnormalities developing after first-line imatinib treatment for chronic phase chronic myeloid leukemia. Am J Hematol 83(9):755, 9/2008. PMID: 18615551.
35. Tam CS, Kantarjian H, Garcia-Manero G, Borthakur G, O'Brien S, Ravandi F, Shan J, Cortes J. Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood 112(3):516-8, 8/2008. PMID: 18492956.
36. Giles FJ, DeAngelo DJ, Baccarani M, Deininger M, Guilhot F, Hughes T, Mauro M, Radich J, Ottmann O, Cortes J. Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia. Semin Oncol 35(1 Suppl 1):S1-17; quiz S18-20, 2/2008. PMID: 18346528.
37. Verma D, Kantarjian H, Jain N, Cortes J. Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha. Leuk Lymphoma 49(7):1399-402, 7/2008. PMID: 18452066.
38. Kantarjian H, O'Brien S, Shan J, Huang X, Garcia-Manero G, Faderl S, Ravandi-Kashani F, Verstovsek S, Beth Rios M, Cortes J. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? Cancer 112(4):837-45, 2/2008. PMID: 18085610.
39. Jabbour E, Kantarjian HM, Jones D, Shan J, O'Brien S, Reddy N, Wierda WG, Faderl S, Garcia-Manero G, Verstovsek S, Rios MB, Cortes J. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia post cytogenetic failure on standard-dose imatinib therapy. Blood 113(10). e-Pub 12/2008. PMID: 19060245.
40. Quintás-Cardama A, Cortes J. Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia. Clin Cancer Res 14(14):4392-9, 7/2008. PMID: 18628453.
41. Quintás-Cardama A, Cortes J. Therapeutic options for patients with clonal and idiopathic hypereosinophia. Expert Opin Investig Drugs 17(7):1039-50, 7/2008. PMID: 18549340.
42. Jabbour E, Kantarjian HM, Jones D, Reddy N, O'Brien S, Garcia-Manero G, Burger J, Cortes J. Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood 112(13). e-Pub 9/2008. PMID: 18818391.
43. Khoury HJ, Guilhot F, Hughes TP, Kim DW, Cortes JE. Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations. Cancer 115(7):1381-1394, 2/2009. e-Pub 2/2009. PMID: 19195046.
44. Verma D, Fava C, Kantarjian H, Cortes J. Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia. Am J Hematol 84(4):256-257, 4/2009. e-Pub 1/2009. PMID: 19260121.
45. Quintás-Cardama A, Kantarjian H, Ravandi F, O'Brien S, Thomas D, Vidal-Senmache G, Wierda W, Kornblau S, Cortes J. Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer 115(11):2482-90, 6/2009. e-Pub 3/2009. PMID: 19280591.
46. Fava C, Kantarjian HM, Jabbour E, O'Brien S, Jain N, Rios MB, Garcia-Manero G, Ravandi F, Verstovsek S, Borthakur G, Shan J, Cortes J. Failure to achieve a complete hematologic response at the time of achievement of a major cytogenetic response with second generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. Blood. e-Pub 3/12/2009. PMID: 19282457.
47. Pavlovsky C, Kantarjian H, Cortes JE. First-line therapy for chronic myeloid leukemia: Past, present, and future. Am J Hematol 84(5):287, 5/2009. e-Pub 2/2009. PMID: 19306355.
48. Jabbour E, Cortes J, Kantarjian H. Treatment selection after imatinib resistance in chronic myeloid leukemia. Target Oncol 4(1). e-Pub 1/30/2009. PMID: 19343297.
49. Quintás-Cardama A, Kantarjian HM, Cortes JE. Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control 16(2):122-31, 4/2009. PMID: 19337198.
50. Quintas-Cardama A, Kantarjian H, Jones D, Shan J, Borthakur G, Thomas D, Kornblau S, O'Brien S, Cortes J. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myelogenous leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood 113(25). e-Pub 4/15/2009. PMID: 19369233.
51. Quintas-Cardama A, Han X, Kantarjian H, Cortes J. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood 114(2):261-3, 5/2009. e-Pub 5/2009. PMID: 19414863.
52. Nussenzveig RH, Cortes J, Sever M, Quintás-Cardama A, Ault P, Manshouri T, Bueso-Ramos C, Prchal JT, Kantarjian H, Verstovsek S. Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001. Int J Hematol. e-Pub 5/30/2009. PMID: 19484334.
53. Kantarjian HM, Shan J, Jones D, O'Brien S, Rios MB, Jabbour E, Cortes J. Significance of Increasing Levels of Minimal Residual Disease in Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia in Complete Cytogenetic Response. J Clin Oncol 27(22):3659-63, 2009. e-Pub 6/2009. PMID: 19487383.
54. Quintás-Cardama A, De Souza Santos FP, Kantarjian H, O'Brien S, Faderl S, Awais A, Borthakur G, Cortes J. Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure. Cancer, 6/2009. e-Pub 6/2009. PMID: 19517473.
55. Verma D, Kantarjian HM, Jones D, Luthra R, Borthakur G, Verstovsek S, Rios MB, Cortes J. Chronic myeloid leukemia (CML) with P190BCR-ABL - analysis of characteristics, outcomes and prognostic significance. Blood. e-Pub 6/2009. PMID: 19531657.
56. Jain N, Reuben JM, Kantarjian H, Li C, Gao H, Lee BN, Cohen EN, Ebarb T, Scheinberg DA, Cortes J. Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a Phase 2 Trial. Cancer, 6/2009. e-Pub 6/2009. PMID: 19536894.
57. Cortes JE, Egorin MJ, Guilhot F, Molimard M, Mahon FX. Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia. Leukemia. e-Pub 4/2009. PMID: 19404318.
58. Jabbour E, Jones D, Kantarjian HM, O'Brien S, Tam C, Koller C, Burger JA, Borthakur G, Wierda WG, Cortes J. Long-term outcome of patients with chronic myeloid leukemia treated with second generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood. e-Pub 6/2009. PMID: 19567878.
59. Cataldo VD, Cortes J, Quintás-Cardama A. Azacitidine for the treatment of myelodysplastic syndrome. Expert Rev Anticancer Ther 9(7):875-84, 7/2009. PMID: 19589026.
60. Szabo SM, Levy AR, Davis C, Holyoake TL, Cortes J. A Multinational Study of Health State Preference Values Associated with Chronic Myelogenous Leukemia. Value Health. e-Pub 7/29/2009. PMID: 19659707.
61. Quintás-Cardama A, Kantarjian H, Cortes J. Imatinib and beyond-exploring the full potential of targeted therapy for CML. Nat Rev Clin Oncol 6(9):535-543, 9/2009. PMID: 19652654.
62. Quintás-Cardama A, Cortes J. Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the best therapy? Curr Oncol Rep 11(5):337-45, 9/2009. PMID: 19679008.

Abstracts
1. Vega-Ruiz A, Cortes JE, Sever M, Manshouri T, Quintás-Cardama A, Luthra R, Kantarjian HM, Verstovsek S. Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res 33(11):1481-4, 11/2009. e-Pub 2/3/2009. PMID: 19193436.
2. Verstovek S, Tefferi A, Kantarjian H, Manshouri T, Luthra R, Pardanani A, Quintas-Cardama A, Ravandi F, Ault P, Buenos-Ramos C, Cotes JE. Alemtuzumab Therapy for Hypereosinophilic Syndrome and Chronic Eosinophilic Leukemia. Clinical Cancer 15(1):368, 1/2009.
3. Cortes J, Keersmaecker KD. T-Cell acute lymphoblastic leukemia with a ''pinch'' of BCR-ABL1. Leuk Lymphoma 50(3):1-2, 3/2009. e-Pub 3/2009. PMID: 19294558.
4. Wetzler M, Hellman A, Lipton J, Roy L, Jones D, Schenk T, Hochhaus A, Benichou A, Kantarjian H, Cortes J. Subcutaneous omacetaxine mepesuccinate in chronic myeloid leukemia (CML) paients resistant or intolerant to two or more tyrosines kinase inhibitors (TKI's): Data from an ongoing phase II trial. Journal of Clinical Oncology 27(15s):362s (#7027), 5/2009.
5. Verma D, Kantarjian H, Jones D, Borthakur G, Garcia-Manero G, Thomas D.A, Verstovsek S, Rios M, Cortes J. Chronic myeloid leukemia (CML) with e1a2 BCR-ABL, fusion transcript type: Analysis of characteristics, outcomes, and prognostic significance. Journal of Clinical Oncology 27(15s):363s (#7030), 5/2009.
6. Alvarado Y, Kantarjian H, O'Brien S, Faderl S, Borthakur G, Burger J, Wierda W, Garcia-Manero G, Shan J, Cortes J. Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer 115(16):3709-18, 8/15/2009. PMID: 19517462.
7. Cortes J.E, Khoury H.J, Corm S, Nicolini F. Schenk T, Jones D, Hochhaus A, Craig A.R, Humphriss E, Kantarjian H. Subcutaneous omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia (CML) patients (Pts) with the T3151 mutation: Data from an ongoing phase IVII trial. Journal of Clinical Oncology 27(15s):358s (#7008), 5/2009.
8. Quintas-Cardama A, Kantarjian H, O'Brien S, Borthakur G, Verstovsek S, Wierda W, Shan J, Cortes J. Prognostic Impact of deletions of derivative chromosome 9 on patients (PTS) with chronic myelogenous leukemia (CML) in chronic phase treated iwth Nilotinib or dasatinib. Blood 112(11):734 (#2110), 11/2009.
9. Fava C, Cortes J. Optimizing first-line therapy for patients with chronic myeloid leukemia. Semin Hematol 46(2 Suppl 3):S5-10, 4/2009. PMID: 19621543.
10. Pavlovsky C, Kantarjian H, Cortes JE. First-line therapy for chronic myeloid leukemia: Past, present, and future. Am J Hematol 84(5):287, 5/2009. PMID: 19306355.
11. Khoury HJ, Guilhot F, Hughes TP, Kim DW, Cortes JE. Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations. Cancer 115(7):1381-1394, 2/2009. PMID: 19195046.
12. Quintás-Cardama A, Kantarjian H, Ravandi F, O'Brien S, Thomas D, Vidal-Senmache G, Wierda W, Kornblau S, Cortes J. Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer 115(11):2482-90, 6/2009. PMID: 19280591.
13. Fava C, Kantarjian HM, Jabbour E, O'Brien S, Jain N, Rios MB, Garcia-Manero G, Ravandi F, Verstovsek S, Borthakur G, Shan J, Cortes J. Failure to achieve a complete hematologic response at the time of achievement of a major cytogenetic response with second generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. Blood, 3/2009. PMID: 19282457.
14. Cortes J, Keersmaecker KD. T-Cell acute lymphoblastic leukemia with a ''pinch'' of BCR-ABL1. Leuk Lymphoma:1-2, 2009. PMID: 19294558.
15. Quintás-Cardama A, Kantarjian HM, Cortes JE. Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control 16(2):122-31, 4/2009. PMID: 19337198.
16. Quintas-Cardama A, Kantarjian H, Jones D, Shan J, Borthakur G, Thomas D, Kornblau S, O'Brien S, Cortes J. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myelogenous leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood 113(25):6315-21, 4/2009. PMID: 19369233.
17. Quintás-Cardama A, Cortes JE, O'Brien S, Ravandi F, Borthakur G, Liu D, Bleickardt E, Chen TT, Kantarjian HM. Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia. Cancer 115(13):2912-21, 4/2009. PMID: 19402171.
18. Quintás-Cardama A, De Souza Santos FP, Kantarjian H, O'Brien S, Faderl S, Awais A, Borthakur G, Cortes J. Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure. Cancer, 6/2009. PMID: 19517473.
19. Alvarado Y, Kantarjian H, O'Brien S, Faderl S, Borthakur G, Burger J, Wierda W, Garcia-Manero G, Shan J, Cortes J. Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer, 6/2009. PMID: 19517462.
20. Verma D, Kantarjian HM, Jones D, Luthra R, Borthakur G, Verstovsek S, Rios MB, Cortes J. Chronic myeloid leukemia (CML) with P190BCR-ABL - analysis of characteristics, outcomes and prognostic significance. Blood, 2009. PMID: 19531657.
21. Jain N, Reuben JM, Kantarjian H, Li C, Gao H, Lee BN, Cohen EN, Ebarb T, Scheinberg DA, Cortes J. Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a Phase 2 Trial. Cancer, 6/2009. PMID: 19536894.
22. Cortes JE, Egorin MJ, Guilhot F, Molimard M, Mahon FX. Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia. Leukemia, 2009. PMID: 19404318.
23. Jabbour E, Jones D, Kantarjian HM, O'Brien S, Tam C, Koller C, Burger JA, Borthakur G, Wierda WG, Cortes J. Long-term outcome of patients with chronic myeloid leukemia treated with second generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood, 2009. PMID: 19567878.
24. Quintas-Cardama A, Han X, Kantarjian H, Cortes J. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood 114(2):261-3, 5/2009. PMID: 19414863.
25. Quintás-Cardama A, Kantarjian H, Cortes J. Imatinib and beyond-exploring the full potential of targeted therapy for CML. Nat Rev Clin Oncol, 2009. PMID: 19652654.
26. Szabo SM, Levy AR, Davis C, Holyoake TL, Cortes J. A Multinational Study of Health State Preference Values Associated with Chronic Myelogenous Leukemia. Value Health, 2009. PMID: 19659707.
27. Quintás-Cardama A, Cortes J. Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the best therapy? Curr Oncol Rep 11(5):337-45, 9/2009. PMID: 19679008.
28. Kantarjian HM, Shan J, Jones D, O'Brien S, Rios MB, Jabbour E, Cortes J. Significance of Increasing Levels of Minimal Residual Disease in Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia in Complete Cytogenetic Response. J Clin Oncol 27(22):3659-63, 2009. PMID: 19487383.

Book Chapters
1. Cortes JE Kantarjian H , Wierda W. Chronic Myeloid Leukemia. In: Conn's Current Therapy, 456-463, 2009.

Last updated: 9/24/2009